Jefferies Group’s Iovance Biotherapeutics IOVA Stock Holding History

Jefferies Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9,200	Closed	-$102K	–	1784
2022 Q2	$102K	Buy	+9,200	New	+$121K	﹤0.01%	1352
2021 Q3	–	Sell	-185,500	Closed	-$4.83M	–	1855
2021 Q2	$4.83M	Buy	+185,500	New	+$4.82M	0.03%	471
2020 Q3	–	Sell	-25,000	Closed	-$686	–	1445
2020 Q2	$686	Sell	25,000 -24,500	-49%	-$805K	0.01%	841
2020 Q1	$1.48M	Buy	49,500 +40,000	+421%	+$1.06M	0.02%	817
2019 Q4	$263K	Buy	+9,500	New	+$216K	﹤0.01%	2118

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Jefferies Group's IOVA Position: Q3 2022 in Review

Jefferies Group sold out of Iovance Biotherapeutics (IOVA) in Q3 2022, closing a stake of 121 shares — an estimated $1.34K sold.

Jefferies Group first reported a position in IOVA in Q4 2015 and held it in 11 quarters. The position peaked at $22.2M in Q4 2020. 242 funds tracked by Wall St. Rank hold IOVA as of Q3 2022.

Jefferies Group reported no remaining Iovance Biotherapeutics position as of Q3 2022 after selling out during the quarter.
Jefferies Group sold 121 Iovance Biotherapeutics shares in Q3 2022, an estimated $1.34K.
Jefferies Group first reported a position in Iovance Biotherapeutics in Q4 2015 and held it in 11 quarters.
Jefferies Group's Iovance Biotherapeutics position peaked at $22.2M in Q4 2020.
242 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.